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Nephrology-Hypertension, University of California San Diego, San Diego, California, USAIntroduction: Hypertensive nephrosclerosis is considered the second most common cause of end-stage
renal disease (ESRD), but it is still an insufficiently studied and controversial disease entity. More infor-
mation on the phenotype and prognosis is needed to improve clinical diagnostics and treatment.
Methods: We included all Norwegian patients with chronic kidney disease (CKD) referred for kidney bi-
opsy between 1988 and 2012 whose clinical presentation was consistent with, but not primarily suspicious
for, hypertensive nephrosclerosis (n ¼ 4920); follow-up continued until 2013.
Results: A total of 918 patients (19%) had biopsy-verified hypertensive nephrosclerosis (i.e., arterio-
nephrosclerosis). Their most common biopsy indications were proteinuria (57%), low estimated glomerular
filtration rate (eGFR) (44%), hematuria (34%), or combinations of these indications. Multivariable logistic
regression analysis revealed that arterionephrosclerosis was significantly associated with higher age, male
sex, not having diabetes, higher blood pressure, lower proteinuria, and not having hematuria (P < 0.01 for
all). Body mass index, cholesterol, high-density lipoprotein cholesterol, and eGFR were not significantly
associated with arterionephrosclerosis (P > 0.05 for all). The most common biopsy-verified diagnoses in
patients fulfilling the clinical criteria for hypertensive nephrosclerosis were arterionephrosclerosis (40%),
glomerulonephritis (22%), and interstitial nephritis (14%), reflecting that the criteria had low sensitivity (0.17)
and high specificity (0.94). ESRD and mortality risks did not differ in patients with arterionephrosclerosis
compared to patients with glomerulonephritis, interstitial nephritis, or other relevant diagnoses (P > 0.1 for
both), whereas patients with diabetic kidney disease had a 2-fold higher risk (P < 0.001 for both).
Conclusion: Arterionephrosclerosis is a high-risk disease, often with an atypical phenotype with proteinuria
and hematuria contributing to low accuracy for current clinical criteria for hypertensive nephrosclerosis.
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International Reports (2020) 5, 339–347hypertensive nephrosclerosis are now assumed to
constitute 45% and 28% of new ESRD cases, respec-
tively.2 However, the US Renal Data System makes a
cautionary note on the reliability of these 2 diagnosis
as primary causes of ESRD, reflecting that our underly-
ing knowledge base, especially for hypertensive neph-
rosclerosis, is quite weak and often not evidence-based.
Nephrosclerosis is diagnosed in the majority of patients
without a kidney biopsy, even though the accuracy of
a clinical nephrosclerosis diagnosis has been highly
debated over the past 2 decades.3–5 Histologic findings
typically include hyalinosis and narrowing of the339
CLINICAL RESEARCH MA Øvrehus et al.: Phenotype and Prognosis in Nephrosclerosisafferent arterioles, global glomerulosclerosis, and inter-
stitial fibrosis, and these are often named
arterionephrosclerosis.
Only a few diagnostic studies with relatively small
patient populations and suboptimal design have been
published,6–11 and prevalence, prognosis, and other
important aspects of the nephrosclerosis phenotype are
not well studied. Clinical criteria for nephrosclerosis—
long-standing hypertension, no diabetes, no hematuria,
and no overt proteinuria—had a positive predictive
value of 97% in African American patients (n ¼ 39),
but it was only 48% in Italian patients (n ¼ 56).9,10
African Americans with 2 risk allele variants of the
apolipoprotein L1 (APOL1) gene have, after receiving
some second environmental hit, a high risk of focal
segmental glomerulosclerosis, arterionephrosclerosis,
HIV nephropathy, and kidney failure.12,13 Recent
findings indicate that pathologic ion-channel creation
leads to disrupted endocytosis, autophagy, and mito-
chondrial dysfunction in the kidneys, which especially
harms terminally differentiated cells such as the
podocytes.13,14 Conversely, in whites arterio-
nephrosclerosis is postulated to more often be due to a
process initiated by hypertension and cardiovascular
risk factors.5 These functional and structural changes
indicate that kidney ischemia could be an important
mechanism, but they could also resemble changes
observed in normal aging. This has led some to ques-
tion whether arterionephrosclerosis is simply an
accelerated normal aging process.15
Therefore, to improve our understanding of hyper-
tensive nephrosclerosis, we describe the clinical
phenotype, prognosis, and diagnostics in white Nor-
wegians with biopsy-verified arterionephrosclerosis.METHODS
The Norwegian Kidney Biopsy Registry has collected
extensive clinical and histopathologic data for all pa-
tients undergoing kidney biopsy in Norway since 1988
(5.0 million inhabitants, >90% whites, and a biopsy
frequency of 150 per million inhabitants per year in
2013).16 The registry classifies the biopsy as arterio-
nephrosclerosis if typical findings occur in the absence
of other primary renal diagnosis. In patients with other
findings (such as diabetes, glomerulonephritis, amy-
loid, and so on), combined with arterionephrosclerosis,
the latter is registered as an additional diagnosis only
and not considered in the current study.
Standard evaluation of kidney biopsies in Norway is
based on light microscopy, immunohistochemistry
(staining for immunoglobulins IgG, IgA, IgM, k/l light
chains, complements C3 and C1q), and electron mi-
croscopy combined with other types of staining as340needed. Each biopsy is first evaluated by an experi-
enced regional nephropathologist and later by the na-
tional registry nephropathologist using the criteria
given in the World Health Organization monographs of
renal disease for consistent diagnoses.17 Typical find-
ings in arterionephrosclerosis are arterial medial
thickening and hyaline arteriolosclerosis in afferent
arterioles, leading to narrowing of the lumen.
Furthermore, arterial medial hypertrophy, intimal
sclerosis, and duplication of elastic laminae may be
seen. Varying degrees of focal glomerular ischemic
changes with thickening and wrinkling of the
glomerular basement membrane, mesangial matrix in-
crease, capillary collapse, and global glomerulosclerosis
along with tubular atrophy and interstitial fibrosis are
also seen.17
In addition, representative clinical data obtained
before the biopsy are provided by the local nephrolo-
gist: the indication(s) for kidney biopsy (nephrotic
syndrome, proteinuria, hematuria, progressive decline
in kidney function, acute decline in kidney function,
nephritic syndrome), age, sex, height, weight, systolic
and diastolic blood pressure, antihypertensive medi-
cation, diabetes mellitus, and selected blood and urine
laboratory values (eGFR, total cholesterol, high-density
lipoprotein cholesterol, proteinuria, hematuria).
To generate a clinically relevant group of patients
with biopsy-verified diagnoses, we excluded patients
whose clinical presentation made arterionephrosclerosis
very unlikely or when a specific diagnosis could be
made with high probability based on clinical criteria
and noninvasive blood testing alone; patients with
nephrotic syndrome, antineutrophilic cytoplasmic nu-
clear antibody–associated vasculitis, anti–glomerular
basement membrane glomerulonephritis, thrombotic
microangiopathy, or light-chain cast nephropathy were
excluded. The included patients thus represented a
relevant mix of cases, consisting of both arterio-
nephrosclerosis and other kidney diseases when arte-
rionephrosclerosis could not be accurately ruled out by
clinical presentation or noninvasive tests.
All patients were observed until December 2012 by
linkage to the Norwegian Cause of Death Registry and
the Norwegian Nephrology Registry. Mandatory
reporting makes both registries more than 99% com-
plete regarding death and ESRD status, respectively.
We used Stata 13 software for statistical analysis (Sta-
taCorp LP, College Station, Texas). Baseline clinical
variables were described as means or percentages, and
we compared the group with arterionephrosclerosis to
those with diabetic kidney disease or glomerulone-
phritis/other diseases using t test or c2 test. We also
used logistic regression to study the association be-
tween arterionephrosclerosis (yes/no) and variousKidney International Reports (2020) 5, 339–347
MA Øvrehus et al.: Phenotype and Prognosis in Nephrosclerosis CLINICAL RESEARCHbaseline characteristics. Prognosis was described with
Kaplan-Meier plots, and the associations of kidney
diagnosis with death and ESRD after adjusting for
covariates were assessed with Cox regression analysis.
Diagnostic accuracy was evaluated as sensitivity/spec-
ificity and positive/negative likelihood ratios, because
these measures are less dependent on prevalence and
enable proper adjustment of pretest probability in in-
dividual patients.
All participants gave informed consent when
included in the Norwegian Kidney Biopsy Registry.
Our study was approved by the Regional Committee for
Medical and Health Research Ethics of Central Norway.
RESULTS
We included 4920 patients with biopsy-verified kidney
diagnoses in whom arterionephrosclerosis could not be
reasonably ruled out with noninvasive methods. Even
though kidney biopsy is rarely performed when hy-
pertensive nephrosclerosis is suspected, 918 (18.6%) of
these relevant patients had arterionephrosclerosis as
the main diagnosis. The majority of these patients with
arterionephrosclerosis underwent biopsy owing to
combinations of proteinuria (57%), low GFR (44%),
and/or hematuria (34%) (Figure 1).
Baseline characteristics are shown in Table 1 by
groups of arterionephrosclerosis, diabetic kidney dis-
ease, and glomerulonephritis/other diseases. The mean
age of patients in the arterionephrosclerosis group was


























Figure 1. Venn diagram showing clinical indications for kidney biopsy in a
the current study. GFR, glomerular filtration rate; eGFR, estimated glomer
Kidney International Reports (2020) 5, 339–347mellitus. Their mean systolic blood pressure was 153
mm Hg, eGFR was 42 ml/min per 1.73 m2, and urine
protein excretion was 1.7 g/day. Compared with the
group with glomerulonephritis/other diseases, this
represented substantially higher age, more males,
higher blood pressure, lower proteinuria, and less often
hematuria (P < 0.001 for all). Correspondingly, patients
with arterionephrosclerosis had higher diastolic blood
pressure, lower body mass index, and lower protein-
uria than those with diabetic kidney disease (P < 0.001
for all).
The multivariate logistic regression analyses pre-
sented in Table 2 showed that arterionephrosclerosis
was significantly associated with higher age, male sex,
not having diabetes, higher blood pressure, not having
hematuria, and lower proteinuria (P < 0.01 for all).
Body mass index, cholesterol, high-density lipoprotein
cholesterol, and eGFR were not associated with a his-
tologic diagnosis of arterionephrosclerosis (P > 0.05 for
all). Higher age and diastolic blood pressure were most
strongly associated with arterionephrosclerosis. For
example, if the diastolic blood pressure increased by 1
SD (i.e., 15 mm Hg), the odds of arterionephrosclerosis
increased by 53% (odds ratio 1.53, P < 0.001). Corre-
sponding standardized odds ratio for age was 1.64 (SD,
17 years, P < 0.001).
Table 3 shows the distributions of histologic di-
agnoses among patients fulfilling the current clinical
diagnostic criteria for hypertensive nephrosclerosis
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Table 1. Baseline characteristics in diabetic kidney disease, arterionephrosclerosis, and glomerulonephritis/other relevant diseases
Characteristics DKD (n [ 258) Significance ANS (n [ 918) Significance GN/Other (n [ 3744)
Age (yr) 55.5 (14.4) a 56.8 (13.9) b 47.9 (17.2)
Male sex 171 (66.2) a 632 (68.8%) b 2253 (60.2)
Body mass index (kg/m2) 27.6 (4.1) b 25.8 (3.4) c 25.4 (3.9)
Diabetes mellitus 228 (88.4) b 87 (9.5) b 201 (5.4)
Systolic blood pressure (mm Hg) 153.9 (24.1) a 152.5 (27.8) b 139.8 (22.5)
Diastolic blood pressure (mm Hg) 84.5 (11.8) b 90.0 (16.0) b 83.6 (13.2)
Cholesterol (mmol/l) 5.2 (1.2) c 5.4 (0.8) a 5.5 (1.3)
HDL cholesterol (mmol/l) 1.25 (0.26) a 1.26 (0.23) c 1.29 (0.26)
Proteinuria (g/24 h) 3.2 (2.8) b 1.7 (2.0) b 2.0 (2.33)
Hematuria 65 (25.2%) c 314 (34.2%) b 2087 (55.7)
eGFR (ml/min per 1.73 m2) 41.1 (29.3) a 42.4 (27.9) b 53.1 (34.3)
ANS, arterionephrosclerosis; DKD, diabetic kidney disease; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein.
aNonsignificant tests with P > 0.05.
bP < 0.001 based on 2-sided t test and c2 tests.
cP < 0.01.
Data are shown as the mean (1 SD) or numbers (percentages).
None of the tests had P 0.01–0.05.
CLINICAL RESEARCH MA Øvrehus et al.: Phenotype and Prognosis in Nephrosclerosisproteinuria <0.5 g/24 hours, no hematuria, and no
diabetes mellitus) as well as all patients included in the
study. Among the 380 patients with positive clinical
criteria, there were 153 with biopsy-verified arterio-
nephrosclerosis. The most common histologic diagnoses
among those with a false-positive clinical diagnosis (227
of 380 patients) were primary glomerulonephritis (82),
acute (33), and chronic (17) tubulointerstitial ne-
phropathy, amyloidosis (15), lupus nephritis (5), and
others (60). There were also 15 cases with normal or
unclassifiable findings. This indicates that the diag-
nostic accuracy of current clinical arterio-
nephrosclerosis criteria was low (Table 4). The clinical
criteria detected only 153 of 918 cases with histopath-
ologic arterionephrosclerosis (sensitivity 0.17), whereas
3775 of 4002 patients without arterionephrosclerosis
had a negative test result (specificity 0.94). Corre-
sponding likelihood ratios were 2.9 for a positive test
result and 0.9 for a negative test result. This means that
a positive test result would increase the post-test
probability of disease moderately, whereas a negativeTable 2. Association between clinical variables and histologically confirm
Unadjusted Age- D
OR 95% CI P value OR 95
Age (per 1 yr) 1.03 1.03 1.04 0.000 1.03 1.03
Male sex (no/yes) 1.44 1.23 1.68 0.000 1.43 1.23
BMI (per 1 kg/m2) 1.02 1.00 1.04 0.06 1.01 0.99
Diabetes mellitus (no/yes) 0.87 0.68 1.11 0.268 0.66 0.52
Systolic BP (per 1 mm Hg) 1.02 1.02 1.02 0.000 1.01 1.01
Diastolic BP (per 1 mm Hg) 1.03 1.03 1.04 0.000 1.03 1.03
Hematuria (no/yes) 0.45 0.38 0.52 0.000 0.53 0.45
Proteinuria (per 1g/24 h) 0.91 0.88 0.94 0.000 0.89 0.86
eGFR (per 1ml/min per 1.73 m2) 0.99 0.99 0.99 0.000 0.99 0.99
Cholesterol (per 1 mmol/l) 0.94 0.88 1.01 0.060 0.94 0.89
HDL cholesterol (per 1mmol/l) 0.69 0.51 0.93 0.020 0.87 0.66
BMI, body mass index; BP, blood pressure; CI, confidence interval; eGFR, estimated glomerular fi
associated with 1-SD increase in x-variable.
Multivariable logistic regression analysis data. Age matching to population-based (older) case
342test result would not give a clinical meaningful
decrease of the disease probability (see the example in
Table 4).
The long-term (25-year) prognosis for patients with
biopsy-verified arterionephrosclerosis, diabetic kidney
disease, and glomerulonephritis/other diagnoses is
shown in Figure 2. The Kaplan-Meier curves represent
the estimated probability of survival (with 95% con-
fidence intervals) for hypothetical cohorts of interest,
not the actual percentage surviving. Figure 2a presents
overall survival curves and numbers at risk and shows
that our cohort of patients with biopsy-verified arte-
rionephrosclerosis has a better survival curve
compared with those with diabetic kidney disease (log
rank P < 0.001) but worse survival compared with
those with glomerulonephritis or other diagnoses at
biopsy (log-rank P < 0.001). After 10 years, approxi-
mately 80% of those with glomerulonephritis, 65% of
arterionephrosclerosis, and only 50% of patients with
diabetic kidney disease would be alive. Figure 2b
presents the ESRD-free survival curves and shows thated nephrosclerosis
sex-adjusted Multivariable
% CI P value OR 95% CI P value OR std 1 SD
1.04 0.000 1.03 1.03 1.04 0.000 1.64 16.9
1.68 0.000 1.30 1.101 1.53 0.004 — —
1.03 0.319 1.01 0.99 1.03 0.773 1.01 3.9
0.85 0.001 0.62 0.46 0.79 0.001 — —
1.02 0.000 1.01 1.00 1.01 0.021 1.15 25.1
1.04 0.000 1.03 1.02 1.04 0.000 1.53 14.5
0.62 0.000 0.48 0.42 0.58 0.000 — —
0.93 0.000 0.87 0.84 0.91 0.000 0.71 2.5
1.00 0.038 1.00 1.00 1.00 0.887 0.99 33.8
1.01 0.079 0.92 0.84 1.00 0.085 0.90 1.2
1.20 0.368 1.10 0.80 1.57 0.967 1.00 0.3
ltration rate; HDL, high-density lipoprotein; OR, odds ratio; OR std, odds ratio for outcome
s did not change results.
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Table 3. Distribution of histopathologic diagnoses in patients








N (%) N (%) N (%)
Amyloidosis 15 (4.0) 139 (2.8) 299 (4.1)
Anti-GBM glomerulonephritis — — 43 (0.6)
Arterionephrosclerosis 153 (40.3) 918 (18.7) 947 (13.0)
Diabetic nephropathy 0 (0.0) 258 (5.2) 359 (4.9)
Focal segmental
glomerulosclerosis
5 (1.4) 218 (4.4) 354 (4.9)
Glomerulonephritis, ANCA/
crescentic




47 (12.4) 1522 (30.9) 1662 (22.9)
Glomerulonephritis,
membranoproliferative
6 (1.7) 56 (1.1) 133 (1.8)
Glomerulonephritis,
membranous
2 (0.4) 118 (2.4) 404 (5.6)
Glomerulonephritis, minimal
change
1 (0.4) 68 (1.4) 226 (3.1)
Glomerulonephritis, other/
unclassified
21 (5.6) 337 (6.8) 399 (5.5)
Interstitial nephritis, chronic 17 (4.4) 183 (3.7) 186 (2.6)
Interstitial nephritis, acute 33 (8.6) 311 (6.3) 316 (4.4)
Light-chain cast
nephropathy/Ig deposit
— — 110 (1.5)
Lupus nephritis 5 (1.3) 199 (4.0) 280 (3.9)
Thrombotic microangiopathy — — 34 (0.5)
Unclassifiable 40 (10.5) 177 (3.6) 186 (2.6)
Normal/very slight and
unspecific changes
15 (4.0) 202 (4.1) 211 (2.9)
Inadequate biopsy material — — 309 (4.3)
Other/rare diagnosis 20 (5.3) 214 (4.3) 242 (3.3)
Sum 380 (100.0) 4920 (100.0) 7261 (100.0)
ANCA, anti-neutrophil cytoplasmic nuclear antibodies; ANS, arterionephrosclerosis;
GBM, glomerular basement membrane; NKBR, Norwegian Kidney Biopsy Register.
aThe table includes all relevant patients in the current study and all biopsies in the
Norwegian Kidney Biopsy Register.
Positive clinical criteria for arterionephrosclerosis were hypertension (>140/90 mm Hg),
proteinuria <0.5 g/24 h, no hematuria, and no diabetes mellitus.
MA Øvrehus et al.: Phenotype and Prognosis in Nephrosclerosis CLINICAL RESEARCHthis cohort of patients with arterionephrosclerosis pa-
tients has a slightly higher ESRD risk than those with
glomerulonephritis. Those with diabetic kidney disease





Sensitivity ¼ TP/(TP þ FN) ¼ 0.167 (95% CI, 0.143–0.192)
Specificity ¼ TN/(TN þ FP) ¼ 0.943 (95% CI, 0.936–0.950)
Illustrative example (post-test odds ¼ pretest odds  LR):
Pretest probability ¼ 0.35: positive test / post-test probability ¼ 0.61 (0.57–0.65)
Negative test / post-test probability ¼ 0.32 (0.31–0.33)
CI, confidence interval; FN, false negative, FP, false positive; LR, likelihood ratio; Sens., sensit
The lower boxe shows how the probability of disease changes with a positive vs. a negative
Kidney International Reports (2020) 5, 339–347cumulative probability of having started renal
replacement therapy after 5 years. Corresponding
numbers for arterionephrosclerosis and glomerulone-
phritis were approximately 10% and 20%, respec-
tively. However, patients with arterionephrosclerosis
or diabetic kidney disease were on average 8 years
older than those with glomerulonephritis or other
diseases. Figures 2c and 2d therefore present overall
mortality and ESRD-free survival curves adjusted to
age 55 years. The age-adjusted morality curves were
similar for arterionephrosclerosis and glomerulone-
phritis, whereas diabetic patients with kidney disease
still had a much worse prognosis. Age-adjusted ESRD
curves showed a similar picture, but with a slightly
higher risk in arterionephrosclerosis compared with
glomerulonephritis.
Cox regression analysis (Table 5) revealed age- and
sex-adjusted hazard ratios for death of 2.0 (P < 0.001)
for diabetic kidney disease and 1.1 (P ¼ 0.46) for pa-
tients with arterionephrosclerosis compared to those
with glomerulonephritis (the reference group). Corre-
sponding hazard ratios for ESRD were 2.2 (P < 0.001)
and 1.1 (P ¼ 0.05), respectively. Additional adjustment
for other risks, such as blood pressure and obesity, as
well as eGFR and proteinuria did not change these
findings. Therefore, patients with arterio-
nephrosclerosis experience risks similar to those with
glomerulonephritis but lower than those of patients
with diabetic kidney disease.DISCUSSION
Current clinical criteria for hypertensive nephro-
sclerosis had low sensitivity but high specificity, and
the associated false-positive cases included a substan-
tial proportion with histopathologic glomerulonephritis
and interstitial nephritis. Many patients with arterio-
nephrosclerosis had substantial proteinuria and other
unconventional characteristics, and the diagnosis car-
ried a substantial risk for ESRD and death.hrosclerosis in relevant biopsy-verified cases
Biopsy findings
ositive Negative
53 (TP) 227 (FP) 380
65 (FN) 3775 (TN) 4540
918 4002 4920
Positive LR ¼ Sens./(1 – Spec.) ¼ 2.94 (95% CI, 2.42–3.56)
Negative LR ¼ (1 – Sens.)/Spec. ¼ 0.88 (95% CI, 0.86–0.91)
ivity; Spec., specificity; TN, true negative; TP, true positive.




Figure 2. Overall (a,d) and end-stage renal disease (ESRD)–free survival (b,d) by kidney diagnosis in biopsy-verified cases. The numbers of
patients at risk during follow-up and censored cases are marked. Kaplan-Meier plots also show data risk-adjusted to age 55 years owing to the
younger age of patients with glomerulonephritis (GN) or other disease (c,d). DKD, diabetic kidney disease.
CLINICAL RESEARCH MA Øvrehus et al.: Phenotype and Prognosis in NephrosclerosisThe diagnostic process of arterionephrosclerosis, the
second most common cause of ESRD,2,16,18 is hampered
by the lack of generally accepted objective criteria.
Schlesinger et al.6 reviewed 43 patients with ESRD who
had presumed arterionephrosclerosis and found thatTable 5. Association between biopsy-verified kidney diagnoses and clinic
Adjusted for age D sex Adjuste
HR 95% CI P value HR
Death
Arterionephrosclerosis 1.09 0.96 1.23 0.18 1.00
Diabetic kidney disease 2.04 1.67 2.50 0.000 1.93
Glomerulonephritis/other 1.00 Reference 1.00
ESRD
Arterionephrosclerosis 1.19 1.03 1.39 0.023 0.92
Diabetic kidney disease 2.89 2.34 3.56 0.000 2.84
Glomerulonephritis/other 1.00 Reference 1.00
BMI, body mass index; BP, blood pressure; CI, confidence interval; ESRD, end-stage renal dis
Data are based on Cox proportional hazard regression analysis.
344few had undergone biopsy and only one of the patients
had biopsy-verified arterionephrosclerosis. Likewise,
Zarif et al.8 evaluated 607 patients with ESRD and
found that less than 30% of 225 patients with hyper-
tensive nephrosclerosis actually fulfilled the clinicalal outcomes after adjusting for various risk factors
d for age D sex D BP D BMI
Adjusted for age D sex D BP D BMI D
eGFR D proteinuria
95% CI P value HR 95% CI P value
0.84 1.20 0.98 0.99 0.82 1.20 0.94
1.42 2.60 0.000 1.81 1.32 2.48 0.000
Reference 1.00 Reference
0.75 1.13 0.43 0.95 0.77 1.17 0.64
2.16 3.75 0.000 2.68 2.00 3.58 0.000
Reference 1.00 Reference
ease; HR, hazard ratio.
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MA Øvrehus et al.: Phenotype and Prognosis in Nephrosclerosis CLINICAL RESEARCHcriteria, kidney biopsy had only been performed in 4
patients; in only one of these were the biopsy findings
consistent with a diagnosis of arterionephrosclerosis.
Furthermore, few previous studies have evaluated the
diagnostic accuracy of the current clinical criteria for
nephrosclerosis.7,9–11 We previously found that disease
was confirmed at biopsy in 38 of 39 patients in the
African American Study of Kidney and Hypertension
study who fulfilled the classic criteria of nephro-
sclerosis (i.e., positive predictive value 0.97).10 How-
ever, patients with negative test results did not have a
kidney biopsy, so we could not calculate sensitivity
and specificity. A similar limitation was present in all
other studies.7,9,11 Our results from this study show
that the clinical criteria used today have suboptimal
diagnostic accuracy; a positive test result can increase
post-test probability moderately, but a negative test
result will not decrease the post-test probability at all.
Hypertension has always been assumed to be an
important element of the nephrosclerosis phenotype,
but the level of blood pressure does not directly predict
degree of end-organ damage.5,19,20 Additional risk
factors, such as age, obesity, hyperlipidemia, smoking,
chronic inflammation, and oxidative stress, are neces-
sary to trigger clinical kidney disease by inducing
arterial stiffening, loss of preglomerular autoregulation,
and ischemia. The biopsy-verified phenotype of white
Northern Europeans in our study displayed some of
these features (age), but we did not find an association
with body mass index or lipids. Systolic blood pressure
has long been recognized as a stronger risk factor for
cardiovascular events compared with diastolic values,
especially for coronary heart disease and in the
elderly.21,22 Less information is available regarding
kidney disease risk, and systolic and diastolic blood
pressure have been found to predict ESRD rather
equally in the general population.23 Many patients had
substantial proteinuria, and although this has been
described in previous case reports and small series,24-26
our data confirm that overt proteinuria is highly
prevalent. Podocyte damage leading to proteinuria and
thereby contributing to tubulointerstitial fibrosis has
recently been identified as an important process in
arterionephrosclerosis as well as other forms of glo-
merulosclerosis.27,28 Hematuria was also common, so
although it decreases the probability of arterio-
nephrosclerosis, it far from excludes the diagnosis.
In line with our findings, a severe prognosis has
been demonstrated for patients with biopsy-verified
nephrosclerosis in the rather few other studies avail-
able. A Japanese study found that 29% of the 401
patients included had severe progression defined as
ESRD, doubling of the serum creatinine level, or a 50%
reduction of eGFR after 5 years of follow-up.29 OtherKidney International Reports (2020) 5, 339–347studies have described that 60% to 65% of patients
with arterionephrosclerosis progressed to ESRD within
10 years, but these patients typically had much more
severe hypertension compared with patients in our
study.30,31 Large population-based studies of hyper-
tensive patients without CKD at baseline have also
demonstrated a strong graded risk with higher blood
pressures starting in the high-normal range and
increasing to a relative risk of 4 in those with severe
hypertension (grade III).32 However, the absolute risk
was very low with, for example, only 199 ESRD events
among 21,340 patients with systolic blood pressure in
the 160- to 180-mm Hg range with follow-up over 25
years—that is, 1% compared with more than 25% in
our study of patients with established biopsy-verified
nephrosclerosis. Furthermore, randomized interven-
tion studies of hypertensive patients with nephro-
sclerosis fail to demonstrate a benefit of
antihypertensive treatment,33 and it has been sug-
gested that many cases of nephrosclerosis could
represent normal aging.34 Therefore, the absolute risk
of developing severe CKD among hypertensive patients
is low, but for those with established hypertensive
nephrosclerosis, the risk of ESRD or death equals the
risk among those with glomerulonephritis or other
classic nondiabetic kidney diseases.
Our findings could have important clinical
consequences. A significant number of false-positive
arterionephrosclerosis cases with undiagnosed IgA ne-
phropathy and other primary glomerulopathies,
amyloidosis, and acute as well as chronic tubulointer-
stitial nephritis could potentially have been offered
different and more specific treatment if they had un-
dergone biopsy. This is in line with a more active use of
kidney biopsy in groups traditionally not offered this
diagnostic test (i.e., the elderly, patients with assumed
diabetic kidney disease, and patients with assumed
arterionephrosclerosis).35,36 However, although kidney
biopsy in general is a safe procedure when performed
lege artis,37 recommendations highlight the need to
ensure that the risk of the procedure and treatment is
acceptable for the patient.38 However, whether and how
much the indications for biopsy should be widened
warrants further discussions and studies.
Some important study limitations merit discussion.
The optimal study design would be to systematically
obtain biopsies and prospectively follow up all incident
patients with a clinical phenotype of hypertensive ne-
phropathy. However, it is unlikely that patients, phy-
sicians, and ethics boards would accept such a liberal
biopsy policy. Thus, we probably need to accept, but
actively recognize, the inherited selection bias in
biopsy-verified studies. Our study probably included
more atypical cases than found in clinical practice, so it345
CLINICAL RESEARCH MA Øvrehus et al.: Phenotype and Prognosis in Nephrosclerosiscould be that we underestimate the diagnostic accuracy
of the current clinical criteria. However, we base our
findings on a large number of biopsy-verified cases
combined with relevant clinical data, which seldom
have been available for studies on hypertensive
nephrosclerosis. A very long follow-up, as in our
study, is also necessary in ESRD studies because pro-
gression is often slow and it may take many years
before differences between various phenotypes and
treatments become clear. Finally, we included only
white Northern European subjects, and generalization
to other regions should be done with caution (and for
African Americans not at all).
In conclusion, the current clinical criteria for arte-
rionephrosclerosis have suboptimal diagnostic accu-
racy in whites because many patients have an atypical
phenotype with proteinuria and hematuria. Arterio-
nephrosclerosis carries an increased ESRD and mortal-
ity risk comparable with other causes of nondiabetic
CKD. Further studies should focus on optimizing the
clinical criteria for hypertensive nephrosclerosis and
developing new diagnostic tests, including evidence-
based indications for kidney biopsy in this large
group of patients with CKD.DISCLOSURE
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